• 1  Vazquez‐Lopez F, Gotor Corrales ML, Coto Segura P, et al. Subjective and objective measurement methods in clinical dermatology from an historical perspective: the long way from Joseph Plenck to validation. Int J Dermatol 2006;45:12424. Cross Ref link Pubmed link
  • 2  Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 2010;19:53949. Cross Ref link Pubmed link
  • 3  Faust HB, Gonin R, Chuang T‐Y, et al. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997;133:14438. Cross Ref link Pubmed link
  • 4  Hahn HB, Chuang T‐Y. Using the Dermatology Index of Disease Severity (DIDS) to assess the responsiveness of dermatitis. Clin Exp Dermatol 2006;31:1922. Cross Ref link Pubmed link
  • 5  Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978;157:23844. Cross Ref link Pubmed link
  • 6  Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991;124:56570. Cross Ref link Pubmed link
  • 7  Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self‐administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:1836. Cross Ref link Pubmed link
  • 8  Sampogna F, Sera F, Mazzotti E, et al. Performance of the self‐administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003;139:3538. Cross Ref link Pubmed link
  • 9  Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004;151:3817. Cross Ref link Pubmed link
  • 10  Gottlieb AB, Chaudhari U, Baker DG, et al. The National Psoriasis Foundation Psoriasis Score (NPF‐PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003;2:2606. Pubmed link
  • 11  Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol 2013;69:9317. Cross Ref link Pubmed link
  • 12  Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:5639. Cross Ref link Pubmed link
  • 13  Berth‐Jones J, Grozinger K, Rainville C, et al. A study examining inter‐ and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006;155:70713. Cross Ref link Pubmed link
  • 14  Berth‐Jones J, Thompson J, Papp K; Copenhagen Psoriasis Working Group. A study examining inter‐rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008;159:40712. Cross Ref link Pubmed link
  • 15  Chularojanamontri L, Griffiths CEM, Chalmers RJG. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol 2013;133:195662. Cross Ref link Pubmed link
  • 16  Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol 2014;134:3518. Cross Ref link Pubmed link
  • 17  Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:20612. Cross Ref link Pubmed link
  • 18  Kacar N, Ergin S, Erdogan BS. The comparison of Nail Psoriasis Severity Index with a less time‐consuming qualitative system. J Eur Acad Dermatol Venereol 2008;22:21922. Pubmed link
  • 19  Garzitto A, Ricceri F, Tripo L, Pescitelli L, Prignano F. Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score. J Am Acad Dermatol 2013;69:10534. Cross Ref link Pubmed link
  • 20  Augustin M, Blome C, Costanzo A, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol 2014;170:5918. Cross Ref link Pubmed link
  • 21  Schmitt J, Langan S, Stamm T, Williams HC. Harmonizing Outcome Measurements in Eczema (HOME) Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol 2011;131:62330. Cross Ref link Pubmed link
  • 22  European Task Force. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task force on atopic dermatitis. Dermatology 1993;186:2331. Cross Ref link Pubmed link
  • 23  Schmitt J, Langan S, Williams HC; European Dermato‐Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:138998. Cross Ref link Pubmed link
  • 24  Schmitt J, Langan S, Deckert S, et al. Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:133747. Cross Ref link Pubmed link
  • 25  Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70:33851. Cross Ref link Pubmed link
  • 26  Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012;67:99106. Cross Ref link Pubmed link
  • 27  Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on atopic dermatitis. Dermatology 1997;195:1019. Cross Ref link Pubmed link
  • 28  Pucci N, Novembre E, Cammarata MG, et al. Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. Allergy 2005;60:11316. Cross Ref link Pubmed link
  • 29  Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient‐oriented SCORAD and Three‐Item Severity score. Curr Probl Dermatol 2011;41:14955. Cross Ref link Pubmed link
  • 30  Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on atopic dermatitis. Dermatology 1997;195:1019. Cross Ref link Pubmed link
  • 31  Harari M, Dreiher J, Czarnowicki T, Ruzicka T, Ingber A. SCORAD 75: a new metric for assessing treatment outcomes in atopic dermatitis. J Eur Acad Dermatol Venereol 2012;26:151015. Cross Ref link Pubmed link
  • 32  Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10:1118. Cross Ref link Pubmed link
  • 33  Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004;150:96102. Cross Ref link Pubmed link
  • 34  Houseman TS, Patel MJ, Camacho F, et al. Use of the Self‐Administered Eczema Area and Severity index by parent caregivers: results of a validation study. Br J Dermatol 2002;147:11928. Cross Ref link Pubmed link
  • 35  Charman CR, Venn AJ, Williams HC. The patient‐orientated eczema measure: development and initial validation of a new tool for measuring atopic eczema from the patient's perspective. Arch Dermatol 2004;140:151319. Cross Ref link Pubmed link
  • 36  Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:1314. Pubmed link
  • 37  Emerson RM, Charman CR, Williams HC. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol 2000;142:28897. Cross Ref link Pubmed link
  • 38  Berth‐Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;135(Suppl. 48):2530. Cross Ref link Pubmed link
  • 39  Charman CR, Venn AJ, Williams HC. Reliability testing of the six area, six sign atopic dermatitis severity score. Br J Dermatol 2002;146:105760. Cross Ref link Pubmed link
  • 40  Wolkerstorfer A, De Waard van der Spek FB, Glazenburg EJ, et al. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre‐screening tool for studies. Acta Derm Venereol 1999;79:3569. Cross Ref link Pubmed link
  • 41  Charman CR, Venn AJ, Williams H, Bigby M. Measuring atopic eczema severity visually: which variables are the most important? Arch Dermatol 2005;141:114651. Cross Ref link Pubmed link
  • 42  Sugarman JL, Fluhr JW, Fowler AJ, et al. The Objective Severity Assessment Atopic Dermatitis score. Arch Dermatol 2003;139:141722. Cross Ref link Pubmed link
  • 43  Angelova‐Fischer I, Bauer A, Hipler UC, et al. The Objective Severity Assessment of Atopic Dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis. Br J Dermatol 2005;153:76773. Cross Ref link Pubmed link
  • 44  Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin‐31 (IL‐31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011;25:3349. Cross Ref link Pubmed link
  • 45  Barratt H, Hamilton F, Car J, Lyons C, Layton A, Majeed A. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009;160:1326. Cross Ref link Pubmed link
  • 46  Witkowski JA, Parish LC. The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol 2004;22:3947. Cross Ref link Pubmed link
  • 47  O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatol Treatment 1998;9:21520. Cross Ref link
  • 48  Burke BM, Cunliffe WJ. The assessment of acne vulgaris – the Leeds technique. Br J Dermatol 1984;111:8392. Cross Ref link Pubmed link
  • 49  Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979;115:5715. Cross Ref link Pubmed link
  • 50  Rizova E, Kligman A. New photographic techniques for clinical evaluation of acne. J Eur Acad Dermatol Venereol 2001;15 (Suppl. 3):1318. Pubmed link
  • 51  Dreno B, Bodokh I, Chivot M, et al. ECLA grading: a system of acne classification for every day dermatological practice. Ann Dermatol Venereol 1999;126:13641. Pubmed link
  • 52  Dreno B, Alirezai M, Auffret N, et al. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venereol 2007;134:4515. Cross Ref link Pubmed link
  • 53  Zaraa I, Belghith I, Ben Alaya N, Trojjet S, Mokni M, Ben Osman A. Severity of acne and its impact on quality of life. Skinmed 2013;11:14853. Pubmed link
  • 54  Goodman GJ, Baron JA. Postacne scarring – a quantitative global scarring system. J Cosmet Dermatol 2006;5:4852. Cross Ref link Pubmed link
  • 55  Dreno B, Khammari A, Orain N, et al. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. Dermatology 2007;214:4651. Cross Ref link Pubmed link
  • 56  Lee DH, Choi YS, Min SU, Yoon MY, Suh DH. Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: A randomized split‐face clinical study. J Am Acad Dermatol 2009;60:8017. Cross Ref link Pubmed link
  • 57  Hon KL, Lam MC, Wong KY, et al. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of the brain‐derived neurotrophic factor and substance P. Br J Dermatol 2007;157:9225. Cross Ref link Pubmed link
  • 58  Ständer S, Blome C, Breil B, et al. Assessment of pruritus – current standards and implications for clinical practice: consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP). Hautarzt 2012;63:5212, 524–31. Cross Ref link Pubmed link
  • 59  Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self‐report instrument for the measurement of pruritus severity. Br J Dermatol 2007;156:66773. Cross Ref link Pubmed link
  • 60  Weisshaar E, Gieler U, Kupfer J, Furue M, Saeki H, Yosipovitch G; International Forum on the Study of Itch. Questionnaires to assess chronic itch: a consensus paper of the special interest group of the International Forum on the Study of Itch. Acta Derm Venereol 2012;92:4936. Cross Ref link Pubmed link
  • 61  Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient‐reported outcome measure to assess psoriasis symptom severity. J Dermatol Treat 2013;24:35660. Cross Ref link
  • 62  Bushnell DM, Martin ML, Scanlon M, Chen T, Chau D, Viswanathan HN. Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory. Qual Life Res 2014;23:897906. Cross Ref link Pubmed link
  • 63  Augustin M, Radtke MA, Zschocke I, et al.The patient benefit index: a novel approach in patient‐defined outcomes measurement for skin diseases. Arch Dermatol Res 2009;301:56171. Cross Ref link Pubmed link
  • 64  Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient‐relevant benefit in the treatment of psoriasis. Arch Dermatol Res 2012;304:43341. Cross Ref link Pubmed link
  • 65  Serup J, Jemec GBE, Grove GL, eds. Handbook of Non‐invasive Methods and the Skin, 2nd edn. Boca Raton, Florida: Taylor and Francis, 2006. Cross Ref link
  • 66  Tan CY, Statham B, Marks R, Payne P. Skin thickness measurement by pulsed ultrasound; its reproducibility, validation and variability. Br J Dermatol 1982;106:65767. Pubmed link
  • 67  Lacarrubba F, Nardone B, Musumeci ML, Micali G. Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot study. Dermatol Ther 2009;22 Suppl. 1:S1921. Cross Ref link Pubmed link
  • 68  Ormerod AD, Dwyer CM, Weller R, et al. A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol 1997;37:517. Cross Ref link Pubmed link
  • 69  Ferguson JS, Yeshanehe WE, Matts PJ, Davey G, Mortimer PS, Fuller LC. Assessment of skin barrier function in podoconiosis: measurement of stratum corneum hydration and transepidermal water loss. Br J Dermatol 2013;168:5504. Cross Ref link Pubmed link
  • 70  Batisse D, Giron F, Leveque JL. Capacitance imaging of the skin surface. Skin Res Technol 2006;12:99104. Cross Ref link Pubmed link
  • 71  Hon KL, Wong KY, Leung TF, et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:4550. Cross Ref link Pubmed link
  • 72  Mogensen M, Morsy HA, Thrane L, Jemec GBE. Morphology and epidermal thickness of normal skin imaged by optical coherence tomography. Dermatology 2008;217:1420. Cross Ref link Pubmed link
  • 73  Fullerton A, Fischer T, Lahti A, et al. Guidelines for measurement of skin colour and erythema. Contact Dermatitis 1996;35:110. Cross Ref link Pubmed link
  • 74  Pladellorens J, Pinto A, Segura J, et al. A device for the color measurement and detection of spots on the skin. Skin Res Technol 2008;14:6570. Pubmed link
  • 75  Stamatas GN, Zmudzka BZ, Kollias N, Beer JZ. Non‐invasive measurements of skin pigmentation in situ. Pigment Cell Res 2004;17:61626. Cross Ref link
  • 76  Zonios G, Bykowski J, Kollias N. Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy. J Invest Dermatol 2001;117:14527. Cross Ref link Pubmed link
  • 77  Hashmi F, Malone‐Lee J. Measurement of skin elasticity on the foot. Skin Res Technol 2007;13:2528. Cross Ref link Pubmed link
  • 78  Kottner J, Schario M, Garcia Bartels N, Pantchechnikova E, Hillmann K, Blume‐Peytavi U. Comparison of two in vivo measurements for skin surface topography. Skin Res Technol 2013;19:8490. Cross Ref link Pubmed link
  • 79  Farhi D, Falissard B, Dupuy A. Global assessment of psoriasis severity and change from photographs: a valid and consistent method. J Invest Dermatol 2008;128:198203.
  • 80  Hani AF, Prakasa E, Nugroho H, Affandi AM, Hussein SH. Body surface area measurement and soft clustering for PASI area assessment. Conf Proc IEEE Eng Med Biol Soc 2012;2012:4398401. Pubmed link
  • 81  Kreft S, Kreft M, Resman A, et al. Computer‐aided measurement of psoriatic lesion area in a multicenter clinical trial – comparison to physician's estimations. J Dermatol Sci 2006;44:217. Cross Ref link Pubmed link
  • 82  Aydin F, Senturk N, Sahin B, et al. A practical method for the estimation of vitiligo surface area: a comparison between the point counting and digital planimetry techniques. Eur J Dermatol 2007;17:302. Pubmed link
  • 83  Finlay AY. Dermatology patients: what do they really need? Clin Exp Dermatol 2000;25:44450. Cross Ref link Pubmed link
  • 84  Koller M, Lorenz W. Quality of Life: a deconstruction for clinicians. J R Soc Med 2002;95:4818. Cross Ref link Pubmed link
  • 85  Naldi L. Health‐related quality of life: from health economics to bedside. Dermatology 2007;215:2736. Cross Ref link Pubmed link
  • 86  Calman KC. Quality of life in cancer patients – an hypothesis. J Med Ethics 1984;10:1247. Cross Ref link Pubmed link
  • 87  Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014;12:4857. Pubmed link
  • 88  All Party Parliamentary Group on Skin. The psychological and social impact of skin diseases on people's lives. A report of the All Party Parliamentary Group on Skin, London, 2013.
  • 89  Katugampola RP, Finlay AY. Impact of skin diseases on quality of life. In: Barker J, Burgdorf W, eds. EDF White Book, 3rd edn. Berlin: European Dermatology Forum (EDF), 2010:1516.
  • 90  Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:7516. Cross Ref link Pubmed link
  • 91  Rapp SR, Feldman SR, Exum L, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:4017. Cross Ref link Pubmed link
  • 92  Jemec GBE, Wulf HC. Patient–physician consensus and quality of life in dermatology. Clin Exp Dermatol 1996;21:1779. Cross Ref link Pubmed link
  • 93  Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol 2002;27:13. Cross Ref link
  • 94  Sampogna F, Gisondi P, Tabolli S, et al. Impairment of sexual life in patients with psoriasis. Dermatology 2007;214:14450. Cross Ref link Pubmed link
  • 95  Kragballe K, Gniadecki R, Mørk NJ, Rantanen T, Ståhle M. Implementing best practice in psoriasis: a Nordic Expert Group Consensus. Acta Derm Venereol 2014;94:54752. Cross Ref link Pubmed link
  • 96  Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005;152:8617. Cross Ref link Pubmed link
  • 97  Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:9871019. Cross Ref link Pubmed link
  • 98  National Institute for Health and Clinical Guidance. CG153. Psoriasis: The Assessment and Management of Psoriasis, October 2012 www.nice.org.uk/guidance/cg153 (last accessed October 2015).
  • 99  Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 2013;54:14854. Cross Ref link Pubmed link
  • 100  Boehncke W‐H, Brasie RA, Barker J, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006;20:98898. Pubmed link
  • 101  VanBeek M, Beach S, Braslow L, et al. Highlights from the report of the Working Group on ‘Core measures of the burden of skin diseases’. J Invest Dermatol 2007;127:27016. Cross Ref link Pubmed link
  • 102  Prinsen CA, de Korte J, Augustin M, et al. EADV Taskforce on Quality of Life. Measurement of health‐related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013;27:1195203. Pubmed link
  • 103  Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997;136:30514. Cross Ref link Pubmed link
  • 104  Hyland ME. A brief guide to the selection of quality of life instrument. Health Qual Life Outcomes 2003;1:24. Cross Ref link Pubmed link
  • 105  Both H, Essink‐Bot M‐L, Busschbach J, Nijsten T. Critical review of generic and dermatology‐specific health‐related quality of life instruments. J Invest Dermatol 2007;127:272639. Cross Ref link Pubmed link
  • 106  Jayaprakasam A, Darvay A, Osborne G, McGibbon D. Comparison of assessments of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002;27:3068. Cross Ref link Pubmed link
  • 107  De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality‐of‐life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002;138:12217. Cross Ref link Pubmed link
  • 108  Chren MM. Understanding research about quality of life and other health outcomes. J Cut Med Surg 1999;3:31216.
  • 109  Finlay AY. Research methodology in quality of life assessment. In: Walker C, Papadopoulos L, eds. Psychodermatology. Cambridge: Cambridge University Press, 2005.
  • 110  Chen SC. Dermatology Quality of Life instruments: sorting out the quagmire. J Invest Dermatol 2007;127:26956. Cross Ref link Pubmed link
  • 111  Mazzotti E, Barbaranelli C, Picardi, et al. Psychometric properties of the Dermatology life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol 2005;85:40913. Cross Ref link Pubmed link
  • 112  Nijsten T, Meads DM, McKenna SP. Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Derm Venereol 2006;86:2845. Cross Ref link Pubmed link
  • 113  Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:65964. Cross Ref link Pubmed link
  • 114  Nijsten T, Sampogna F, Abeni D. Categorization of Skindex‐29 scores using mixture analysis. Dermatology 2009;218:1514. Cross Ref link Pubmed link
  • 115  Rogers A, DeLong LK, Chen SC. Clinical Meaning in Skin‐specific Quality of Life Instruments: A Comparison of the Dermatology Life Quality Index and Skindex Banding Systems. Dermatol Clin 2012;30:33342. Cross Ref link Pubmed link
  • 116  Nijsten T, Meads DM, de Korte J, et al. Cross‐cultural inequivalence of dermatology‐specific health‐related quality of life instruments in psoriasis patients. J Invest Dermatol 2007;127:231522. Cross Ref link Pubmed link
  • 117  Bergner M, Bobbit RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787805. Cross Ref link Pubmed link
  • 118  Prins M, Krabbe PFM, Swinkels QOJ, et al. The effect of treatment on quality of life in psoriasis patients. Acta Derm Venereol 2005;85:30410. Pubmed link
  • 119  Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. Br J Dermatol 1993;129:42230. Cross Ref link Pubmed link
  • 120  Ware JE, Sherbourne CD. The MOS 36‐Item Short‐Form Health Survey (SF‐36). 1. Conceptual framework and item selection. Med Care 1992;30:43783.
  • 121  Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF‐36. Br J Dermatol 2006;154:8449. Cross Ref link Pubmed link
  • 122  Fernandez‐Peñas P, Jones‐Caballero M, Espallardo O, García‐Díez A.Comparison of Skindex‐29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.Br J Dermatol 2012;166:8847. Cross Ref link Pubmed link
  • 123  Engin B, Uguz F, Yilmaz E, et al. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008;22:3640. Pubmed link
  • 124  Skevington SM, Bradshaw J, Hepplewhite A, et al. How does psoriasis affect quality of life? Assessing an Ingram‐regimen outpatient programme and validating the WHOQOL‐100. Br J Dermatol 2006;154:68091. Cross Ref link Pubmed link
  • 125  Martin F, Camfield L, Rodham, et al. Twelve years' experience with the Patient Generated Index (PGI) of quality of life: a graded structured review. Qual Life Res 2007;16:70515. Cross Ref link Pubmed link
  • 126  Kind P, Gudex C, Dolan P, Williams A. Practical and methodological issues in the development of the EuroQol: the York experience. Adv Med Sociol 1994;5:21953.
  • 127  Szende A, Oppe M, Devlin N, eds. EQ‐5D Value Sets: inventory, comparative review and user guide. Berlin: Springer, 2007. Cross Ref link
  • 128  Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ‐5D in the economic evaluation of dermatological conditions and therapies. Dermatology 2012;225:4553. Cross Ref link Pubmed link
  • 129  Picardi A, Abeni D, Pasquini P. Assessing psychological distress in patients with skin diseases: reliability, validity and factor structure of the GHQ‐12. J Eur Acad Dermatol Venereol 2001;15:41017. Cross Ref link Pubmed link
  • 130  Cohen AD, Ofek‐Shlomai A, Vardy DA, et al. Depression in dermatological patients identified by the Mini International Neuropsychiatric Interview questionnaire. J Am Acad Dermatol 2006;54:949. Cross Ref link Pubmed link
  • 131  Staubach P, Eckhardt‐Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired by psychiatric comorbidity. Br J Dermatol 2006;154:2948. Cross Ref link Pubmed link
  • 132  Finlay AY, Khan GK. Dermatology Life quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:21016. Cross Ref link Pubmed link
  • 133  Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a Quality‐of‐life measure for patients with skin diseases: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:70713. Cross Ref link Pubmed link
  • 134  Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of Life scales – a measure of the impact of skin diseases. Br J Dermatol 1997;136:2026. Cross Ref link Pubmed link
  • 135  Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997;37:4150. Cross Ref link Pubmed link
  • 136  Schafer T, Staudt A, Ring J. German instrument for the assesment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Hautarzt 2001;52(7):6248. Cross Ref link Pubmed link
  • 137  Grob JJ, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152:28995. Cross Ref link Pubmed link
  • 138  Gurel MS, Yanik M, Simsek Z, et al. Quality of life instrument for Turkish people with skin diseases. Int J Dermatol 2005;44:9338. Cross Ref link Pubmed link
  • 139  Augustin M, Bross F, Foldi E, et al. Development, validation and clinical use of the FLQA‐I, a disease‐specific quality of life questionnaire for patients with lymphedema. Vasa 2005;34:315. Cross Ref link Pubmed link
  • 140  Mühleisen B, Büchi S, Schmidhauser S, Jenewein J, French LE, Hofbauer GF. Pictorial Representation of Illness and Self Measure (PRISM): A novel visual instrument to measure quality of life in dermatological inpatients. Arch Dermatol 2009;145:77480. Cross Ref link Pubmed link
  • 141  Evers AWM, Duller P, van de Kerkhof PCM, et al. The impact of chronic skin disease on daily life (ISDL): a generic and dermatology‐specific health instrument. Br J Dermatol 2008;158:1018. Pubmed link
  • 142  Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003;148:27984. Cross Ref link Pubmed link
  • 143  Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:9971035. Pubmed link
  • 144  Dermatology Life Quality Index (DLQI): Department of Dermatology, Cardiff University www.cardiff.ac.uk/dermatology/quality‐of‐life/ (last accessed October 2015).
  • 145  Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000;143:97982. Cross Ref link Pubmed link
  • 146  Badia X, Mascaro JM, Lozano R. Measuring health‐related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensibility to change of the DLQI. Br J Dermatol 1999;141:698702. Cross Ref link Pubmed link
  • 147  Augustin M, Zschocke I, Lange S, et al. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999;50:71522. Cross Ref link Pubmed link
  • 148  Zachariae R, Zachariae C, Ibsen H, et al. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol 2000;80:2726. Cross Ref link Pubmed link
  • 149  Hahn BH, Melfi CA, Chuang TY, et al. Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US urban clinic. J Am Acad Dermatol 2001;45:448. Cross Ref link Pubmed link
  • 150  Mork C, Wahl A, Moum T. The Norwegian version of the Dermatology Life Quality Index: a study of validity and reliability in psoriatics. Acta Derm Venereol 2002;82:32751.
  • 151  Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:31822. Cross Ref link Pubmed link
  • 152  Szepietowski J, Salomon J, Finlay AY, et al. Dermatology Life Quality Index (DLQI): Polish version. Dermatol Kliczna 2004;6:6370.
  • 153  Aghaei S, Sodaifi M, Jafari P, et al. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004;4:8 Cross Ref link Pubmed link
  • 154  Ferraz LB, Almeida FA, Vasconcellos MR, et al. The impact of lupus erythematosus on the quality of life: the Brazilian‐Portugese version of DLQI. Qual Life Res 2006;15:56570. Cross Ref link Pubmed link
  • 155  Takahashi N, Suzukamo Y, Nakamura M, et al. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006;4:46. Cross Ref link Pubmed link
  • 156  Madarasingha NP, de Silva P, Satgurunathan K.Validation study of Sinhala version of the dermatology life quality index (DLQI). Ceylon Med J 2011;56:1822. Pubmed link
  • 157  Melilli L, Shikiar R, Thompson C. Minimum clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with Adalimumab. J Am Acad Dermatol 2005;52 (Suppl.):AB221.
  • 158  Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005;3:36. Cross Ref link Pubmed link
  • 159  Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147 (Suppl. 62):50.
  • 160  Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015;230:2733. Cross Ref link Pubmed link
  • 161  Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol 2012;132:1113. Cross Ref link Pubmed link
  • 162  Finlay AY, Basra MK, Piguet V, Salek MS. Dermatology life quality index (DLQI): a paradigm shift to patient‐centered outcomes. J Invest Dermatol 2012;132:24645. Cross Ref link Pubmed link
  • 163  Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality‐of‐life instrument for patients with skin diseases. Arch Dermatol 1997;133:143340. Cross Ref link Pubmed link
  • 164  Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex‐16: a brief quality‐of‐life measure for patients with skin diseases. J Cutan Med Surg 2001;5:10510. Cross Ref link Pubmed link
  • 165  Nijsten TEC, Sampogna F, Chren M‐M, Abeni DD. Testing and reducing Skindex‐29 using Rasch analysis: Skindex‐17. J Invest Dermatol 2006;126:124450. Cross Ref link Pubmed link
  • 166  Jones‐Caballero M, Penas PF, Garcia‐Diaz A, et al. The Spanish version of Skindex‐29. Int J Dermatol 2000;39:90712. Cross Ref link Pubmed link
  • 167  Abeni D, Picardi A, Pasquini P, et al. Further evidence of the validity and reliability of the Skindex‐29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002;204:439. Cross Ref link Pubmed link
  • 168  Aksu AEK, Urer MS, Sabuncu I, et al. Turkish version of Skindex‐29. Int J Dermatol 2007;46:3505. Cross Ref link Pubmed link
  • 169  Al Ghamdi KM, Al Shammari SA. Arabic version of Skindex‐16: translation and cultural adaptation, with assessment of reliability and validity. Int J Dermatol 2007;46:24752. Cross Ref link Pubmed link
  • 170  Higaki Y, Kawamoto K, Kamo T, et al. The Japanese version of Skindex‐16: a brief quality‐of‐life measure for patients with skin disease. J Dermatol 2002;29:6938. Cross Ref link Pubmed link
  • 171  Augustin M, Wenninger K, Amon U, et al. German adaptation of the Skindex‐29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology 2004;209:1420. Cross Ref link Pubmed link
  • 172  Chua SL, Maurer T, Chren MM. Adaptation of a Runyankore version of Skindex‐16 for oral administration in Mbarara, Uganda. Int J Dermatol 2011;50:124954. Cross Ref link Pubmed link
  • 173  El Fakir S, Baybay H, Bendahhou K, et al. Validation of the Skindex‐16 questionnaire in patients with skin diseases in Morocco. J Dermatol Treat 2014;25:1069. Cross Ref link
  • 174  Bronsard V, Paul C, Prey S, et al.What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24 Suppl. 2:1722. Cross Ref link Pubmed link
  • 175  Thomas CL, Finlay AY. Measuring the effects of psoriasis on quality of life. Exp Rev Dermatol 2006;1(5):7236. Cross Ref link
  • 176  De Korte J, Sprangers MAG, Mombers FMC, Bos JD. Quality of life measures in psoriasis: a systematic literature review. J Invest Dermatol Symp Proc 2004;9:1407. Cross Ref link
  • 177  Finlay AY, Kelly SE. Psoriasis – an index of disability. Clin Exp Dermatol 1987;12:811. Cross Ref link Pubmed link
  • 178  Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:23644. Cross Ref link Pubmed link
  • 179  Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:72936. Cross Ref link Pubmed link
  • 180  Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology 2005;210:2618. Cross Ref link Pubmed link
  • 181  Garcia‐Diez A, Foraster CF, Sebastian FV, et al. What characterizes the severity of psoriasis? Dermatology 2008;216:13751. Cross Ref link Pubmed link
  • 182  Nijsten T, Whalley D, Gelfand J, et al. The psychometric properties of the psoriasis disability index in United States patients. J Invest Dermatol 2005;125:66572. Cross Ref link Pubmed link
  • 183  Ginsberg IH, Link BG. Feelings of stigmatisation in patients with psoriasis. J Am Acad Dermatol 1989;20:5363. Cross Ref link Pubmed link
  • 184  Schmid‐Ott G, Jaeger B, Ott R, Lamprecht F. Dimensions of stigmatisation in patients with psoriasis in a ‘questionnaire on experience with skin complaints’. Dermatology 1996;193:30410. Cross Ref link Pubmed link
  • 185  Vardy D, Besser A, Amir M, et al. Experiences of stigmatisation play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002;147:73642. Cross Ref link Pubmed link
  • 186  Zachariae R, Zachariae H, Blomqvist K, et al. Self‐reported stress reactivity and psoriasis‐related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 2004;18:2736. Cross Ref link Pubmed link
  • 187  Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis‐related stress. Acta Dermatol Venereol (Stockh) 1995;75:2403.
  • 188  McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16‐center PUVA follow‐up cohort. J Am Acad Dermatol 1997;36:38894. Cross Ref link Pubmed link
  • 189  Nijsten T, Unaeze J, Stern RS. Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis. Br J Dermatol 2006;154:692700. Cross Ref link Pubmed link
  • 190  Unaeze J, Nijsten T, Murphy A, et al. Impact of psoriasis on health‐related quality of life decreases over time: an 11‐year prospective study. J Invest Dermatol 2006;126:14809. Cross Ref link Pubmed link
  • 191  McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003;149:32331. Cross Ref link Pubmed link
  • 192  McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: a psoriasis‐specific measure of quality of life. Int J Dermatol 2005;44:4629. Cross Ref link Pubmed link
  • 193  Mease PJ, Menter MA. Quality‐of‐life issues in psoriasis and psoriatic arthritis outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685704. Cross Ref link Pubmed link
  • 194  Feldman SR, Koo JYM, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol 2005;53:1017. Cross Ref link Pubmed link
  • 195  Sampogna F, Styles I, Tabolli S, Abeni D. Measuring quality of life in psoriasis: the CALIPSO questionnaire. Eur J Dermatol 2011;21:6778. Pubmed link
  • 196  Fivenson D, Arnold RJG, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002;8:33342.
  • 197  Finlay AY. The burden of atopic eczema. In: Ring J, Przybila B, Ruzicka T, eds. Handbook of Atopic Eczema, 2nd edn. Berlin: Springer, 2006.
  • 198  Ando T, Hashiro M, Noda K, et al. Development and validation of the psychosomatic scale for atopic dermatitis in adults. J Dermatol 2006;33:43950. Cross Ref link Pubmed link
  • 199  Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res 2004;57:195200. Cross Ref link Pubmed link
  • 200  Chamlin SL, Cella D, Frieden IJ, et al. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality‐of‐life measure for young children with atopic dermatitis and their families. J Invest Dermatol 2005;125:110611. Cross Ref link Pubmed link
  • 201  Chamlin SL, Lai J‐S, Cella D, et al. Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity and responsiveness. Arch Dermatol 2007;143:76872. Cross Ref link Pubmed link
  • 202  Neri E, Agostini F, Gremigni P, et al. Italian validation of the Childhood Atopic Dermatitis Impact Scale: a contribution to its clinical application. J Invest Dermatol 2012;132:253443. Cross Ref link Pubmed link
  • 203  McKenna SP, Whalley D, Dewar AL, et al. International development of the parents' index of quality of life in atopic dermatitis (PIQoL‐AD). Qual Life Res 2005;14:23141. Cross Ref link Pubmed link
  • 204  Meads DM, McKenna SP, Kahler K. The quality of life of parents of children with atopic dermatitis; interpretation of PIQoL scores. Qual Life Res 2005;14:223545. Cross Ref link Pubmed link
  • 205  Lawson V, Lewis‐Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaire. Br J Dermatol 1998;138:10713. Cross Ref link Pubmed link
  • 206  Lewis‐Jones MS, Finlay AY, Dykes PJ. The Infant's Dermatitis Quality of Life Index. Br J Dermatol 2001;144:10410. Cross Ref link Pubmed link
  • 207  Basra MK, Gada V, Ungaro S, Finlay AY, Salek SM. Infants' Dermatitis Quality of Life Index: a decade of experience of validation and clinical application. Br J Dermatol 2013;169:7608. Cross Ref link Pubmed link
  • 208  Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992;17:13. Cross Ref link Pubmed link
  • 209  Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol 1989;14:1948. Cross Ref link Pubmed link
  • 210  Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Qual Life Res 1996;5:1318. Cross Ref link Pubmed link
  • 211  Dreno B, Finlay AY, Nocera T, et al. The Cardiff Acne Disability Index: cultural and linguistic validation in French. Dermatology 2004;208:1048. Cross Ref link Pubmed link
  • 212  Aghaei S, Mazharinia N, Jafari P, Abbasfard Z. The Persian version of the Cardiff Acne Disability Index. Saudi Med J 2006;27:4479.
  • 213  Jankovic S, Vukicevic J, Djordjevic S, Jankovic J, Marinkovic J, Basra MK. The Cardiff Acne Disability Index (CADI): linguistic and cultural validation in Serbian. Qual Life Res 2013;22:1616. Cross Ref link Pubmed link
  • 214  Walker N, Lewis‐Jones MS. Quality of life and acne in Scottish adolescent schoolchildren: use of the Children's Dermatology Life Quality Index (CDLQI) and the Cardiff Acne Disability Index (CADI). J Eur Acad Dermatol Venereol 2006;20:4550. Cross Ref link Pubmed link
  • 215  Layton AM. Psychological assessment of skin disease. Interfaces Dermatol 1994;1:379.
  • 216  Zauli S, Caracciolo S, Borghi A, et al. Which factors influence quality of life in acne patients? J Eur Acad Dermatol Venereol 2014;28:4650. Cross Ref link Pubmed link
  • 217  Gupta MAA, Johnson AM, Gupta AK. The development of an acne quality of life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol (Stockh) 1998;78:4516. Cross Ref link
  • 218  Martin AR, Lookingbill DP, Botek A, et al. Health‐related quality of life among patients with facial acne – assessment of a new acne‐specific questionnaire. Clin Exp Dermatol 2001;26:3805. Cross Ref link Pubmed link
  • 219  Tan J, Fung KY, Khan S. Condensation and validation of a 4‐item index of the Acne‐QoL. Qual Life Res 2006;15:120310. Cross Ref link Pubmed link
  • 220  Tan J, O'Toole A, Zhang X, Dreno B, Poulin Y. Evaluation of the French version of the 4‐item index of the Acne‐QoL (AcneQ4fr). Qual Life Res 2013;22:5479. Cross Ref link Pubmed link
  • 221  Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient‐reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol 2014;13:33340. Pubmed link
  • 222  Ruta DA, Garratt AM, Leng M, et al. A new approach to the measurement of quality of life. The patient generated index. Med Care 1994:32:110926. Cross Ref link Pubmed link
  • 223  Herd RM, Tidman MJ, Ruta DA, Hunter JAA. Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods. Br J Dermatol 1997;136: 5027. Cross Ref link Pubmed link
  • 224  Lundberg L, Johanesson M, Silverdahl, et al. Quality of life, health state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:106775. Cross Ref link Pubmed link
  • 225  Schiffner R, Schiffner‐Rohe JS, Gerstenhauer M, et al. Willingness to pay and time trade‐off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003;148:115360. Cross Ref link Pubmed link
  • 226  Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996;7:14954. Cross Ref link
  • 227  Cham PMH, Chen SC, Grill JP, et al. Reliability of self‐reported willingness‐to‐pay and annual income in patients treated for toenail onychomycosis. Br J Dermatol 2007;156:9228. Cross Ref link Pubmed link
  • 228  Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K. Measuring melasma patients' quality of life using willingness to pay and time trade‐off methods in Thai population. BMC Dermatol 2011 Dec 19;11:16. Cross Ref link Pubmed link
  • 229  Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population‐based study. Br J Dermatol 2008;158:3519. Cross Ref link Pubmed link
  • 230  Chen SC, Bayoumi AM, Soon SL, et al. A catalog of dermatologic utilities: a measure of the burden of skin diseases. J Invest Dermatol Symp Proc 2004;9:1608. Cross Ref link
  • 231  Simpson NB. Social and economic aspects of acne and the cost‐effectiveness of isotretinoin. J Dermatol Treat 1993;4 (Suppl. 2):S69. Cross Ref link
  • 232  Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1233. Pubmed link
  • 233  Lloyd A, Reeves P, Conway P, et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009;160:3806. Cross Ref link Pubmed link
  • 234  Stevens KJ, Brazier JE, McKenna SP, et al. The development of a preference‐based measure of health in children with atopic dermatitis. Br J Dermatol 2005;153:3727. Cross Ref link Pubmed link
  • 235  Pitt M, Garside R, Stein K. A cost–utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006;154:113746. Cross Ref link Pubmed link
  • 236  Parsi K, Chambers CJ, Armstrong AW. Cost‐effectiveness analysis of a patient‐centered care model for management of psoriasis. J Am Acad Dermatol 2012;66:56370. Cross Ref link Pubmed link
  • 237  Solans M, Pane S, Estrada MD, et al. Health‐related quality‐of‐life measurement in children and adolescents: a systematic review of generic and disease‐specific instruments. Value Health 2007;11:74264. Cross Ref link Pubmed link
  • 238  Brown MM, Chamlin SL, Smidt AC. Quality of life in pediatric dermatology. Dermatol Clin 2013;31:21121. Cross Ref link Pubmed link
  • 239  Lewis‐Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:9429. Cross Ref link Pubmed link
  • 240  Holme SA, Mann I, Sharpe JL, et al. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003;148:28590. Cross Ref link Pubmed link
  • 241  Salek MS, Jung S, Brincat‐Ruffini LA, et al. Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995–2012. Br J Dermatol 2013;169:73459. Cross Ref link Pubmed link
  • 242  Rauch PK, Jellinek MS, Murphy JM, et al. Screening for psychosocial dysfunction in pediatric dermatology practice. Clin Pediar 1991;30:4937. Cross Ref link
  • 243  Golics CJ, Basra MKA, Finlay AY, Salek MS. Adolescents with skin disease have specific quality of life issues. Dermatology 2009;218:35766. Cross Ref link Pubmed link
  • 244  Smidt AC, Lai J‐S, Cella D, Patel S, Mancini AJ, Chamlin S. Development and Validation of Skindex‐Teen, a quality‐of‐life instrument for adolescents with skin disease. Arch Dermatol 2010;146:8659. Cross Ref link Pubmed link
  • 245  Basra MK, Finlay AY, Salek S. Development and validation of Teenager's quality of life (T‐QoL)© Index: a dermatology specific measure for adolescents. J Invest Dermatol 2013;133 (Suppl. 1):S95.
  • 246  Basra MKA, Finlay AY. The family impact of skin disease: the Greater Patient concept. Br J Dermatol 2007;156:92937. Cross Ref link Pubmed link
  • 247  Moore K, David TJ, Murray CS, et al. Effect of childhood eczema and asthma on parental sleep and well‐being: a prospective comparative study. Br J Dermatol 2006;154:51418. Cross Ref link Pubmed link
  • 248  Von Reuden U, Staab D, Kehrt R, Wahn U. Development of a questionnaire to measure health‐related quality of life in parents of children with atopic dermatitis. Qual Life Res 1998;7:6567.
  • 249  Chamlin SL, Cella D, Frieden IJ, et al. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality‐of‐life measure for young children with atopic dermatitis and their families. J Invest Dermatol 2005;125:110611. Cross Ref link Pubmed link
  • 250  Dodington SR, Basra MK, Finlay AY, Salek MS. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol 2013;169:3146. Cross Ref link Pubmed link
  • 251  Ben‐Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol 2002;16:45562. Cross Ref link Pubmed link
  • 252  Chamlin SL, Chren MM. Quality‐of‐life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am 2010;30:2818. Cross Ref link Pubmed link
  • 253  Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 2007;215:1239. Cross Ref link Pubmed link
  • 254  Basra MKA, Sue‐Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007;156:52838. (Erratum. Br J Dermatol 2007;156:791.) Cross Ref link Pubmed link
  • 255  Basra MKA, Edmunds O, Salek MS, Finlay AY. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol 2008;22:81321. Cross Ref link Pubmed link
  • 256  Richards HL, Fortune DG, Chong S, et al. Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol 2004;123:4956. Cross Ref link Pubmed link
  • 257  Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major impact on the lives of family members and partners. Br J Dermatol 2007;156:124550. Cross Ref link Pubmed link
  • 258  Basra MK, Zammit AM, Kamudoni P, Eghlileb AM, Finlay AY, Salek MS. PFI‐14©: A Rasch Analysis Refinement of the Psoriasis Family Index. Dermatology 2015;231(1):1523. Cross Ref link Pubmed link
  • 259  Richards HL, Fortune DG, Griffiths CEM. The Greater Patient concept. Br J Dermatol 2008;158:1768. Pubmed link
  • 260  Golics CJ, Basra MK, Finlay AY, Salek S. The development and validation of the Family Reported Outcome Measure (FROM‐16)© to assess the impact of disease on the partner or family member. Qual Life Res 2014;23:31726. Cross Ref link Pubmed link
  • 261  Golics CJ, Basra MK, Salek MS, Finlay AY. The impact of patients' chronic disease on family quality of life: an experience from 26 specialties. Int J Gen Med 2013;6:78798. Cross Ref link Pubmed link
  • 262  Finlay AY. The three dimensions of skin disease burden: ‘now’, ‘long term’ and ‘family’. Br J Dermatol 2013;169:9634. Cross Ref link Pubmed link
  • 263  Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010;24:9891004. Pubmed link
  • 264  Bhatti Z, Salek M, Finlay A. Chronic diseases influence major life changing decisions: a new domain in quality of life research. J R Soc Med 2011;104:24150. Cross Ref link Pubmed link
  • 265  Bhatti ZU, Finlay AY, Bolton CE, et al. Chronic disease influences over 40 major life‐changing decisions (MLCDs): a qualitative study in dermatology and general medicine. J Eur Acad Dermatol Venereol 2014 Oct;28(10):134455. Cross Ref link Pubmed link
  • 266  Bhatti ZU, Salek SS, Bolton CE, et al. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes 2013;11:78. Cross Ref link Pubmed link
  • 267  Feldman S, Behnam SM, Behnam SE, Koo JYM. Involving the patient: impact of inflammatory skin disease and patient‐focused care. J Am Acad Dermatol 2005;53:S7885. Cross Ref link Pubmed link
  • 268  Dubertret L. Patient‐based medicine. J Eur Acad Dermatol Venereol 2006;20 (Suppl. 2):736. Cross Ref link
  • 269  Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient‐rated quality of life. Br J Dermatol 2005;152:125662. Cross Ref link Pubmed link
  • 270  David SE, Ahmed Z, Salek MS, Finlay AY. Does enough quality‐of ‐life related discussion occur during dermatology outpatient consultations? Br J Dermatol 2005;153:9971000. Cross Ref link Pubmed link
  • 271  Salek S, Roberts A, Finlay AY. The practical reality of using a patient‐reported outcome measure in a routine dermatology clinic. Dermatology 2007;215:31519. Cross Ref link Pubmed link
  • 272  Chren M‐M. Measurement of vital signs for skin diseases. J Invest Dermatol 2005;125(4):viiiix. Cross Ref link Pubmed link
  • 273  Naldi L. Health‐Related quality of life: from health economics to bedside? Dermatology 2007;215:2736. Cross Ref link Pubmed link